By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...

Sanofi’s multiple sclerosis medicine tolebrutinib was recommended for approval by European regulators, a boost for the ...

The oral BTK inhibitor race in RMS is now a two-horse affair, with fenebrutinib vying against Novartis' remibrutinib, already ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

Add Yahoo as a preferred source to see more of our stories on Google. A logo of Sanofi at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, ...

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said ...

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...